EUVIMEDEUVIMED entdecken
Crossref

Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer

Mohamed A Schumann, Aurélie Gaasch, Sandra Boyaci, Frederik Fuchs, Franziska Walter, Sebastian N Marschner, Chukwuka Eze, Christoph Benedikt Westphalen, Julian Walter Holch, Georg Beyer, Wolfgang G Kunz, Julia Mayerle und 4 weitere

World Journal of Gastroenterology · 07.08.2026 · 32 (29)

DOI: 10.3748/wjg.117832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 07.08.2026. Verfasst von Mohamed A Schumann und 15 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with most patients present with or develop metastatic disease. Despite modern multiagent chemotherapy, survival remains poor. Locoregional progression of the primary tumor often causes pain, biliary obstruction, and gastrointestinal complications. Magnetic resonance-guided radiotherapy (MRgRT) enables daily adaptive planning and real-time motion control, allowing safe dose escalation in anatomically constrained regions. We hypothesized that stereotactic magnetic resonance–guided radiotherapy provides effective and safe local tumor control in patients with metastatic PDAC (mPDAC). AIM To investigate the feasibility, efficacy, and safety of MRgRT in mPDAC. METHODS This prospective single-center observational study enrolled consecutive patients with synchronous or metachronous mPDAC treated between January 2020 and January 2025. Radiotherapy was delivered on a 0.35-T MR-Linac with 33-40 Gy in five fractions. Primary endpoint was local control; secondary endpoints included overall survival (OS), time to distant progression, toxicity, and pain relief. Prognostic clinical and treatment parameters were explored using subgroup analyses. RESULTS Twenty-four patients were included. Local control at 12 months and 24 months was 76% and 67%, respectively. Median time to distant progression was 3 months. Median OS in the entire cohort was 13 months after radiotherapy and 20 months from diagnosis, with a 1-year OS rate of 49%. Palliative treatment intent was associated with shorter survival (5 months, P = 0.001). OS was longer in patients with single-organ disease (P = 0.003), stable metastatic disease after systemic therapy (P = 0.0027), carbohydrate antigen 19-9 < 500 U/mL (P = 0.03), and Eastern Cooperative Oncology Group 0 (P = 0.023). Two acute grade 3 gastrointestinal events (duodenal hemorrhage, biliary duct obstruction) occurred; no late grade ≥ 3 toxicities were observed. Pain relief was reported by 89% of symptomatic patients. CONCLUSION MRgRT is a feasible and well-tolerated treatment providing high local control and effective pain palliation in selected patients with mPDAC.

Zitieren

APA

Schumann, M. A., Gaasch, A., Boyaci, S., Fuchs, F., Walter, F., Marschner, S. N., Eze, C., Westphalen, C. B., Holch, J. W., Beyer, G., Kunz, W. G., Mayerle, J., Niyazi, M., Belka, C., Corradini, S., & Rogowski, P. (2026). Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World Journal of Gastroenterology, 32(29). https://doi.org/10.3748/wjg.117832

Vancouver

Schumann MA, Gaasch A, Boyaci S, Fuchs F, Walter F, Marschner SN, et al. Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World Journal of Gastroenterology. 2026;32(29). doi:10.3748/wjg.117832

BibTeX
@article{Schumann2026,
  author = {Schumann, Mohamed A and Gaasch, Aurélie and Boyaci, Sandra and Fuchs, Frederik and Walter, Franziska and Marschner, Sebastian N and Eze, Chukwuka and Westphalen, Christoph Benedikt and Holch, Julian Walter and Beyer, Georg and Kunz, Wolfgang G and Mayerle, Julia and Niyazi, Maximilian and Belka, Claus and Corradini, Stefanie and Rogowski, Paul},
  title = {Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer},
  journal = {World Journal of Gastroenterology},
  year = {2026},
  volume = {32},
  number = {29},
  doi = {10.3748/wjg.117832}
}
Kostenlos starten →